B-cell lymphoma is a cancer that starts in B-lymphocytes, a type of white blood cell responsible for producing antibodies to fight infections. It is the most common category of non-Hodgkin lymphoma, and it ranges from slow-growing forms that may not need immediate treatment to fast-growing types that require aggressive therapy. Understanding the specific subtype matters because it determines how the disease behaves and how it’s treated.
How B Cells Become Cancerous
B cells are uniquely vulnerable to becoming cancerous because of the very process that makes them useful. To fight a wide range of infections, B cells constantly rearrange and edit their own DNA to produce different antibodies. That DNA-editing machinery occasionally misfires, causing chromosomal breaks and mutations that activate genes promoting uncontrolled growth.
Once a B cell picks up these errors, it can hijack the signaling pathways that normal B cells use to survive and multiply. In healthy cells, these pathways switch on when the body encounters a threat, then switch off. In cancerous B cells, they stay permanently active through mutations that either supercharge growth signals or disable the molecular brakes meant to keep growth in check. The result is a population of abnormal B cells that accumulates in lymph nodes, bone marrow, or other organs instead of dying on schedule.
Indolent vs. Aggressive Subtypes
B-cell lymphomas fall into two broad camps: indolent (slow-growing) and aggressive (fast-growing). The distinction is critical because it shapes everything from symptoms to urgency of treatment.
Follicular lymphoma is the most common indolent subtype. It often develops quietly over months or years, sometimes discovered incidentally during imaging for something else. Many people with early-stage follicular lymphoma are monitored without immediate treatment, a strategy called “watch and wait.” The trade-off is that indolent lymphomas are harder to cure outright and can, over time, transform into an aggressive lymphoma, typically diffuse large B-cell lymphoma. When that transformation happens, it’s usually marked by rapidly enlarging lymph nodes or worsening symptoms.
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive subtype and the most common type of lymphoma overall, though it’s still relatively uncommon. In 2020, roughly 6 in 100,000 people received a DLBCL diagnosis. It grows quickly and can be life-threatening, but that rapid growth also makes it more responsive to treatment. Other aggressive subtypes include intravascular large B-cell lymphoma, which grows inside blood vessels, and certain rare forms with specific genetic rearrangements.
Common Symptoms
The most noticeable sign of B-cell lymphoma is a swollen lymph node, usually in the neck, armpits, or groin. It typically feels like a painless lump that doesn’t go away and gradually gets larger. Nodes larger than 1 centimeter that feel firm or rubbery, are fixed in place, or are painless are more concerning than small, tender, freely movable nodes (which are far more likely caused by infection).
About 30% of people with DLBCL also experience what clinicians call “B symptoms”: unexplained fevers above 38°C lasting more than a month, drenching night sweats that soak through sheets, and unintentional weight loss of more than 10% of body weight within six months. People with aggressive lymphomas tend to have more pronounced B symptoms and faster-growing nodes. Other general symptoms include fatigue, pain, shortness of breath, and an enlarged spleen.
How It’s Diagnosed
Diagnosing B-cell lymphoma requires a tissue biopsy, not just blood work or imaging. A surgeon removes all or part of an affected lymph node so pathologists can examine the cells under a microscope and run specialized tests to identify the exact subtype. Needle biopsies sometimes provide enough tissue, but a larger excisional biopsy (removing the entire node) is often preferred because it preserves the architecture of the tissue, which is important for accurate classification.
Once a diagnosis is confirmed, imaging scans map how far the disease has spread. Staging follows the Ann Arbor system: Stage I means lymphoma is confined to a single region, Stage II involves multiple regions on the same side of the diaphragm, Stage III means both sides are affected, and Stage IV indicates widespread involvement. For DLBCL, 37% of cases are diagnosed at Stage IV, while only 20% are caught at Stage I.
Risk Factors
Several factors increase the likelihood of developing B-cell lymphoma. Viral infections play a notable role. The Epstein-Barr virus (the virus behind mononucleosis) infects more than 90% of people worldwide and is linked to about 1% of global cancers, including certain B-cell lymphomas. People with EBV-positive DLBCL tend to have a more aggressive disease course. HIV, hepatitis B, and hepatitis C have also been associated with higher lymphoma risk.
A weakened immune system, whether from an inherited condition, organ transplant medications, or HIV, is another established risk factor. Certain autoimmune conditions that cause chronic immune stimulation can also push B cells toward malignant transformation over time.
Treatment for Aggressive B-Cell Lymphoma
The standard first-line treatment for DLBCL is a combination regimen known as R-CHOP, which pairs a targeted therapy with chemotherapy and a steroid. The targeted drug attaches to a specific protein found on the surface of B cells, essentially flagging them so the immune system can find and destroy them. The chemotherapy drugs kill rapidly dividing cells, and the steroid reduces inflammation and enhances the effects of the other drugs. Treatment is typically given in cycles over several months.
R-CHOP is effective for the majority of people. The overall five-year relative survival rate for DLBCL is about 65%. Caught at Stage I, that number jumps to 80%. Even at Stage IV, it’s roughly 56%, reflecting the fact that aggressive lymphomas often respond well to treatment even when widespread.
Treatment for Indolent B-Cell Lymphoma
Indolent lymphomas like follicular lymphoma are managed differently. Because they grow slowly and may cause few symptoms for years, early-stage disease is sometimes monitored without treatment. When treatment becomes necessary, it often involves a similar combination of targeted therapy and chemotherapy, though the intensity and specific drugs may differ. The goal shifts depending on the situation: sometimes it’s long-term disease control rather than outright cure, since indolent lymphomas have a tendency to recur.
When Lymphoma Comes Back
For people whose B-cell lymphoma returns after initial treatment or doesn’t respond to it, a newer option called CAR-T cell therapy has become standard of care. In this approach, a sample of your own immune cells is collected, genetically modified in a lab to recognize and attack a protein on B-cell lymphoma cells, and then infused back into your body. The engineered cells can find and kill cancer cells independently, without relying on traditional chemotherapy.
CAR-T therapy is currently used for people with aggressive B-cell lymphomas who have already gone through at least two rounds of prior treatment. Clinical trials have shown meaningful responses even in patients whose disease had resisted everything else. The treatment involves a single infusion but requires close monitoring afterward, typically in a specialized center, because the sudden immune activation can cause significant side effects in the days and weeks following treatment.